Recommendations for immunocytochemistry in lung cancer typing: An update on a resource-efficient approach with large-scale comparative Bayesian analysis

Basit Öğe Kaydı
dc.contributor.authorElmas, Hatice
dc.contributor.authorDiel, Roland
dc.contributor.authorOnal, Binnur
dc.contributor.authorSauter, Guido
dc.contributor.authorStellmacher, Florian
dc.contributor.authorWelker, Lutz
dc.date.accessioned2021-12-01T18:50:29Z
dc.date.available2021-12-01T18:50:29Z
dc.date.issued2021
dc.department[Belirlenecek]en_US
dc.description.abstractObjectives The majority of lung cancer cases are of advanced stage and diagnosis is usually made using minimally invasive small biopsies and cytological specimens. The WHO 2015 classification recommends limiting immunocytochemistry (ICC) to lung cancer typing and molecular testing drives for personalised therapies. An algorithm using Bayes' theorem could be useful for defining antibody profiles. This study aims to assess the impact of different antibody profiles for cytological samples on the accuracy of lung cancer typing with a large-scale Bayesian analysis. Methods A retrospective examination of 3419 consecutive smears and/or cytospins diagnosed over 2011-2016 found 1960 primary lung cancer tumours: 972 adenocarcinomas (ADC), 256 squamous carcinomas (SQC), 268 neuroendocrine tumours (NET), and 464 non-small cell cancer-not otherwise specified (NSCC-NOS). The a priori and a posteriori probabilities, before and after ICC using antibodies singly or in combination, were calculated for different lung cancer types. Results TTF-1 or CK7 alone improved the a posteriori probabilities of correct cytological typing for ADC to 86.5% and 95.8%, respectively. For SQC, using p40 ( increment Np63) or CK5/6 together with CK5/14 led to comparable results (78.3% and 90.3%). With synaptophysin or CD56 alone, improvements in a posteriori probabilities to 87.5 and 90.3% for the correct recognition of NET could be achieved. Conclusions Based on morphological and clinical data, the use of two antibodies appears sufficient for reliable detection of the different lung cancer types. This applies to diagnoses that were finalised following ICC both on a clinical or cytological basis and on a histological basis.en_US
dc.identifier.doi10.1111/cyt.13051
dc.identifier.issn0956-5507
dc.identifier.issn1365-2303
dc.identifier.pmid34402101en_US
dc.identifier.scopus2-s2.0-85115704631en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1111/cyt.13051
dc.identifier.urihttps://hdl.handle.net/20.500.12684/10885
dc.identifier.wosWOS:000699409600001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofCytopathologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBayes theoremen_US
dc.subjectcytologyen_US
dc.subjectimmunocytochemistryen_US
dc.subjectlung canceren_US
dc.subjecttumor typingen_US
dc.subjectSquamous-Cell Carcinomaen_US
dc.subjectDiagnosisen_US
dc.subjectAdenocarcinomaen_US
dc.subjectP40en_US
dc.subjectImmunohistochemistryen_US
dc.subjectSubclassificationen_US
dc.subjectNapsinen_US
dc.subjectMarkeren_US
dc.subjectP63en_US
dc.titleRecommendations for immunocytochemistry in lung cancer typing: An update on a resource-efficient approach with large-scale comparative Bayesian analysisen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
10885.pdf
Boyut:
3.7 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu